A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Criterium
- 28 Jul 2022 Status changed from completed to discontinued.
- 22 Jul 2020 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.